X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (31192) 31192
Newsletter (3437) 3437
Publication (3284) 3284
Newspaper Article (1649) 1649
Book Review (378) 378
Book Chapter (177) 177
Dissertation (53) 53
Conference Proceeding (46) 46
Magazine Article (25) 25
Government Document (14) 14
Book / eBook (13) 13
Trade Publication Article (13) 13
Web Resource (10) 10
Reference (6) 6
Transcript (4) 4
Streaming Video (2) 2
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (20246) 20246
epidermal growth factor (17310) 17310
index medicus (15664) 15664
oncology (11920) 11920
cancer (9841) 9841
animals (9174) 9174
female (7769) 7769
research (6797) 6797
mutation (6536) 6536
receptor, epidermal growth factor - metabolism (6517) 6517
male (5803) 5803
receptor, epidermal growth factor - antagonists & inhibitors (5535) 5535
receptor, epidermal growth factor - genetics (5435) 5435
lung cancer (5427) 5427
signal transduction (5138) 5138
kinases (5114) 5114
phosphorylation (4906) 4906
cell line, tumor (4781) 4781
cell biology (4670) 4670
chemotherapy (4659) 4659
gefitinib (4611) 4611
care and treatment (4557) 4557
tyrosine (4550) 4550
egfr (4412) 4412
mice (4383) 4383
lung cancer, non-small cell (4327) 4327
growth-factor receptor (4240) 4240
genetic aspects (4124) 4124
biochemistry & molecular biology (4108) 4108
expression (4075) 4075
epidermal growth factor receptor (4072) 4072
middle aged (4064) 4064
tumors (4025) 4025
epidermal-growth-factor (3869) 3869
proteins (3853) 3853
aged (3726) 3726
analysis (3556) 3556
lung neoplasms - drug therapy (3533) 3533
metastasis (3475) 3475
lung neoplasms - genetics (3267) 3267
epidermal growth factor receptors (3133) 3133
apoptosis (3109) 3109
antineoplastic agents - therapeutic use (3096) 3096
adult (3012) 3012
carcinoma, non-small-cell lung - drug therapy (2958) 2958
cancer therapies (2882) 2882
breast cancer (2856) 2856
erlotinib (2832) 2832
activation (2799) 2799
antineoplastic agents - pharmacology (2569) 2569
gene expression (2568) 2568
lung neoplasms - pathology (2562) 2562
health aspects (2549) 2549
carcinoma, non-small-cell lung - genetics (2394) 2394
prognosis (2339) 2339
oncology, experimental (2338) 2338
signal transduction - drug effects (2286) 2286
article (2278) 2278
tyrosine kinase inhibitor (2198) 2198
protein kinase inhibitors - therapeutic use (2145) 2145
cell lung-cancer (2138) 2138
epidermal growth factor - pharmacology (2106) 2106
medicine (2105) 2105
adenocarcinoma (2068) 2068
research article (2049) 2049
quinazolines - pharmacology (2024) 2024
therapy (1991) 1991
pharmacology & pharmacy (1958) 1958
protein kinase inhibitors - pharmacology (1931) 1931
aged, 80 and over (1924) 1924
development and progression (1923) 1923
quinazolines - therapeutic use (1904) 1904
cell proliferation (1843) 1843
immunohistochemistry (1833) 1833
carcinoma, non-small-cell lung - pathology (1822) 1822
survival (1797) 1797
cells, cultured (1793) 1793
tyrosine kinase (1775) 1775
multidisciplinary sciences (1770) 1770
cell proliferation - drug effects (1751) 1751
tyrosine kinase inhibitors (1749) 1749
reports (1734) 1734
patients (1733) 1733
rats (1714) 1714
non-small cell lung cancer (1695) 1695
physiological aspects (1670) 1670
cells (1645) 1645
treatment outcome (1629) 1629
cell line (1617) 1617
factor receptor (1600) 1600
medical prognosis (1595) 1595
breast-cancer (1560) 1560
ligands (1554) 1554
respiratory system (1549) 1549
medical research (1543) 1543
growth factors (1510) 1510
mutations (1510) 1510
egf receptor (1508) 1508
medicine & public health (1502) 1502
cetuximab (1484) 1484
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (35860) 35860
Chinese (279) 279
French (121) 121
German (68) 68
Japanese (65) 65
Korean (35) 35
Spanish (18) 18
Russian (15) 15
Polish (13) 13
Hungarian (12) 12
Czech (4) 4
Italian (4) 4
Portuguese (4) 4
Dutch (2) 2
Norwegian (2) 2
Danish (1) 1
Persian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Science, ISSN 1347-9032, 08/2016, Volume 107, Issue 8, pp. 1134 - 1140
Journal Article
Cancer, ISSN 0008-543X, 12/2013, Volume 119, Issue 24, pp. 4325 - 4332
Journal Article
by Xu, R and Shao, H and Zhu, J and Ju, QQ and Shi, H
MEDICINE, ISSN 0025-7974, 03/2019, Volume 98, Issue 13, p. e14135
Background: Combination therapy based on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is an emerging trend in cancer treatment,... 
PLACEBO | METAANALYSIS | epidermal growth factor receptor | erlotinib | gefitinib | METASTATIC COLORECTAL-CANCER | CHEMOTHERAPY | CELL LUNG-CANCER | TRIAL | MEDICINE, GENERAL & INTERNAL | RANDOMIZED PHASE-II | DOUBLE-BLIND | combination therapy | Antineoplastic Agents, Immunological - administration & dosage | Carcinoma, Non-Small-Cell Lung - radiotherapy | Lung Neoplasms - drug therapy | Bevacizumab - pharmacology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Lung Neoplasms - mortality | Humans | Colorectal Neoplasms - radiotherapy | Lung Neoplasms - radiotherapy | Lung Neoplasms - pathology | Protein Kinase Inhibitors - adverse effects | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Colorectal Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - pathology | Colorectal Neoplasms - mortality | Gefitinib - pharmacology | ErbB Receptors - antagonists & inhibitors | Bevacizumab - administration & dosage | Erlotinib Hydrochloride - administration & dosage | Carcinoma, Non-Small-Cell Lung - mortality | Antineoplastic Agents, Immunological - pharmacology | Randomized Controlled Trials as Topic | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Drug Therapy - methods | Erlotinib Hydrochloride - pharmacology | Radiotherapy - methods | Gefitinib - administration & dosage | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Colorectal Neoplasms - pathology | Chemotherapy | Drug therapy, Combination | Patient outcomes | Methods | Cancer
Journal Article
Lung Cancer, ISSN 0169-5002, 2016, Volume 93, pp. 59 - 68
Highlights • 3rd generation EGFR TKIs are T790M selective with minimal inhibition in WT EGFR. • The 3rd generation EGFR TKIs are highly active and are well... 
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | Osimertinib | Rociletinib | HM61713 | Tyrosine kinase inhibitor | Epidermal growth factor receptor mutations | Non-small cell lung cancer | GEFITINIB | ADENOCARCINOMA | ACQUIRED-RESISTANCE | EGFR MUTATIONS | COMBINATION | CHEMOTHERAPY | HETEROGENEITY | CIRCULATING TUMOR DNA | ONCOLOGY | RESPIRATORY SYSTEM | AZD9291 | VEMURAFENIB | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Antineoplastic Agents - pharmacology | Drug Evaluation, Preclinical | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Treatment Outcome | Clinical Trials as Topic | Blood-Brain Barrier - drug effects | Carcinoma, Non-Small-Cell Lung - mortality | Drug Discovery | Blood-Brain Barrier - metabolism | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Tyrosine | Lung cancer, Non-small cell | Epidermal growth factor | Chemotherapy | Phenols | Lung cancer, Small cell | Development and progression | Metastasis | Cancer
Journal Article
Lung Cancer, ISSN 0169-5002, 2012, Volume 77, Issue 3, pp. 556 - 560
Abstract Non-small cell lung cancer (NSCLC) harboring an activating epidermal growth factor receptor (EGFR) mutation shows good and rapid response to EGFR... 
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | EGFR mutation | EGFR TKI | Erlotinib | Gefitinib | Brain metastasis | Non-small cell lung cancer | SURVIVAL | MANAGEMENT | ADENOCARCINOMA | PHASE-II | RADIATION | CHEMOTHERAPY | ONCOLOGY | RESPIRATORY SYSTEM | NEVER-SMOKERS | RADIOTHERAPY | 1ST-LINE THERAPY | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Sequence Deletion | Exons | Lung Neoplasms - mortality | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Brain Neoplasms - secondary | Carcinoma, Non-Small-Cell Lung - secondary | Adult | Female | Antineoplastic Agents - pharmacology | Brain Neoplasms - mortality | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Brain Neoplasms - genetics | Treatment Outcome | Brain Neoplasms - drug therapy | Disease-Free Survival | Point Mutation | Quinazolines - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Quinazolines - pharmacology | Tyrosine | Brain | Care and treatment | Oncology, Experimental | Brain tumors | Radiosurgery | Metastasis | Research | Lung cancer, Non-small cell | Epidermal growth factor | Phenols | Genetic aspects | Health aspects | Cancer
Journal Article
Cancer Letters, ISSN 0304-3835, 2012, Volume 328, Issue 1, pp. 144 - 151
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2016, Volume 11, Issue 1, p. e0147344
Epithelial-mesenchymal transition (EMT) is one mechanism of acquired resistance to inhibitors of the epidermal growth factor receptor-tyrosine kinases... 
TARGETED THERAPY | SIGNALING PATHWAYS | GEFITINIB | TGF-BETA | MULTIDISCIPLINARY SCIENCES | SENSITIVITY | MECHANISMS | E-CADHERIN | MESENCHYMAL TRANSITION | MIR-200 FAMILY | REPRESSORS ZEB1 | Lung Neoplasms - drug therapy | RNA, Small Interfering - genetics | Homeodomain Proteins - metabolism | Humans | Lung Neoplasms - metabolism | ErbB Receptors - genetics | Drug Resistance, Neoplasm | Lung Neoplasms - pathology | Immunoenzyme Techniques | Epithelial-Mesenchymal Transition | Antineoplastic Agents - pharmacology | Tumor Cells, Cultured | Real-Time Polymerase Chain Reaction | Carcinoma, Non-Small-Cell Lung - pathology | ErbB Receptors - antagonists & inhibitors | ErbB Receptors - metabolism | RNA, Messenger - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Transcription Factors - antagonists & inhibitors | Transcription Factors - genetics | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | Homeodomain Proteins - genetics | Transcription Factors - metabolism | Homeodomain Proteins - antagonists & inhibitors | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Zinc Finger E-box-Binding Homeobox 1 | Antimitotic agents | Complications and side effects | Genetic aspects | Dosage and administration | Research | Lung cancer, Non-small cell | Drug therapy | Drug resistance | Antineoplastic agents | Vimentin | Smad protein | Transcription factors | Mesenchyme | Lung cancer | Oncology | Metastasis | Kinases | E-cadherin | Cell adhesion & migration | Chronic exposure | c-Met protein | Genotype & phenotype | Epidermal growth factor | Trends | MET protein | Protein-tyrosine kinase | Informatics | Tyrosine | Hematology | Epidermal growth factor receptors | Environmental health | Non-small cell lung carcinoma | Gene expression | Medicine | Gene amplification | Inhibitors | DNA microarrays | Ribonucleic acids | Epigenetics | Tumors | Cancer
Journal Article